Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario.
Diaz H, Jiménez J, Hernández A, Valdés L, Martínez A, Porto L, Hernández R, Travieso N, Jova JH, Medel L, Troche M, Gorte A, Batista D, Valls AR, Cabrera L, Domeq M, Pérez L, Lorenzo-Luaces P, Sánchez L, Saavedra D, Ramos M, Crombet T. Diaz H, et al. Among authors: ramos m. Front Public Health. 2022 Jul 22;10:948520. doi: 10.3389/fpubh.2022.948520. eCollection 2022. Front Public Health. 2022. PMID: 35937253 Free PMC article.
Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody.
Saavedra D, Añé-Kourí AL, Gregorich EML, Mena J, Lorenzo-Luaces P, Londres HD, Martínez AH, Armada JJ, Sánchez YH, González YZ, Troche M, Medel L, Ramos M, Crombet T. Saavedra D, et al. Among authors: ramos m. Immunol Lett. 2022 Dec;251-252:1-8. doi: 10.1016/j.imlet.2022.09.005. Epub 2022 Sep 27. Immunol Lett. 2022. PMID: 36174772 Free PMC article.
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.
Caballero A, Filgueira LM, Betancourt J, Sánchez N, Hidalgo C, Ramírez A, Martinez A, Despaigne RE, Escalona A, Diaz H, Meriño E, Ortega LM, Castillo U, Ramos M, Saavedra D, García Y, Lorenzo G, Cepeda M, Arencibia M, Cabrera L, Domecq M, Estévez D, Valenzuela C, Lorenzo P, Sánchez L, Mazorra Z, León K, Crombet T. Caballero A, et al. Among authors: ramos m. Clin Transl Immunology. 2020 Nov 25;9(11):e1218. doi: 10.1002/cti2.1218. eCollection 2020. Clin Transl Immunology. 2020. PMID: 33304584 Free PMC article.
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
Filgueira LM, Cervantes JB, Lovelle OA, Herrera C, Figueredo C, Caballero JA, Sánchez N, Berrio J, Lorenzo G, Cepeda M, Ramos M, Saavedra D, Añe-Kouri AL, Mazorra Z, Leon K, Crombet T, Caballero A. Filgueira LM, et al. Among authors: ramos m. Immunotherapy. 2021 Mar;13(4):289-295. doi: 10.2217/imt-2020-0235. Epub 2021 Jan 5. Immunotherapy. 2021. PMID: 33397150 Free PMC article.
Nimotuzumab: beyond the EGFR signaling cascade inhibition.
Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. Mazorra Z, et al. Among authors: ramos m. Semin Oncol. 2018 Jan;45(1-2):18-26. doi: 10.1053/j.seminoncol.2018.04.008. Epub 2018 May 2. Semin Oncol. 2018. PMID: 30318080 Free article. Review.
An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.
Saavedra D, Añé-Kourí AL, Sánchez N, Filgueira LM, Betancourt J, Herrera C, Manso L, Chávez E, Caballero A, Hidalgo C, Lorenzo G, Cepeda M, Valenzuela C, Ramos M, León K, Mazorra Z, Crombet T. Saavedra D, et al. Among authors: ramos m. Immun Ageing. 2020 Nov 14;17(1):34. doi: 10.1186/s12979-020-00207-8. Immun Ageing. 2020. PMID: 33292350 Free PMC article.
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A. Crombet T, et al. Among authors: ramos m. J Clin Oncol. 2004 May 1;22(9):1646-54. doi: 10.1200/JCO.2004.03.089. J Clin Oncol. 2004. PMID: 15117987 Clinical Trial.
Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA, Perera A, Batista JF, Hernández A, Crombet T, Ramos M, Neninger E, Pérez M, Sánchez EL, Romero S, Aguilar V, Coca MA, Iznaga-Escobar N. Torres LA, et al. Among authors: ramos m. Nucl Med Commun. 2005 Dec;26(12):1049-57. doi: 10.1097/00006231-200512000-00002. Nucl Med Commun. 2005. PMID: 16264350 Clinical Trial.
2,957 results